Your browser is no longer supported. Please, upgrade your browser.
Settings
ONCY [NASD]
Oncolytics Biotech Inc.
Index- P/E- EPS (ttm)-0.43 Insider Own1.80% Shs Outstand44.14M Perf Week-25.44%
Market Cap155.69M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float42.76M Perf Month-5.68%
Income-17.90M PEG- EPS next Q-0.14 Inst Own2.50% Short Float3.46% Perf Quarter4.18%
Sales- P/S- EPS this Y62.70% Inst Trans53.92% Short Ratio0.70 Perf Half Y41.37%
Book/sh0.45 P/B6.64 EPS next Y- ROA-66.80% Target Price- Perf Year112.06%
Cash/sh0.48 P/C6.25 EPS next 5Y- ROE-96.60% 52W Range1.28 - 4.83 Perf YTD25.63%
Dividend- P/FCF- EPS past 5Y13.60% ROI- 52W High-40.99% Beta2.76
Dividend %- Quick Ratio12.50 Sales past 5Y- Gross Margin- 52W Low122.66% ATR0.38
Employees25 Current Ratio12.50 Sales Q/Q- Oper. Margin- RSI (14)39.65 Volatility12.68% 12.05%
OptionableNo Debt/Eq0.02 EPS Q/Q70.30% Profit Margin- Rel Volume0.45 Prev Close2.99
ShortableYes LT Debt/Eq0.01 EarningsMar 05 BMO Payout- Avg Volume2.13M Price2.85
Recom- SMA20-21.36% SMA50-13.87% SMA20015.60% Volume833,819 Change-4.68%
Feb-17-21Initiated H.C. Wainwright Buy $15
Apr-14-21 05:37AM  
Apr-12-21 10:23AM  
07:02AM  
07:00AM  
Apr-09-21 11:56AM  
11:52AM  
Apr-08-21 07:00AM  
07:00AM  
Apr-05-21 07:00AM  
Mar-25-21 08:44AM  
Mar-23-21 12:22PM  
Mar-10-21 04:32PM  
04:32PM  
Mar-05-21 07:32AM  
07:32AM  
07:30AM  
07:30AM  
06:30AM  
Mar-02-21 03:20PM  
Feb-26-21 07:00AM  
07:00AM  
Feb-23-21 07:00AM  
Feb-17-21 10:12AM  
10:07AM  
09:56AM  
Feb-08-21 08:00AM  
Jan-20-21 07:00AM  
Jan-13-21 08:00AM  
Dec-23-20 06:46AM  
Dec-11-20 12:57PM  
Dec-09-20 09:30AM  
09:30AM  
Nov-26-20 06:15PM  
Nov-19-20 09:05AM  
09:05AM  
Nov-17-20 09:05AM  
Nov-11-20 04:01PM  
04:01PM  
03:15PM  
Nov-09-20 07:05AM  
Nov-06-20 07:00AM  
Oct-27-20 07:00AM  
Oct-19-20 07:00AM  
07:00AM  
Oct-12-20 09:36AM  
Oct-07-20 07:00AM  
07:00AM  
Sep-01-20 09:25AM  
Aug-26-20 07:00AM  
07:00AM  
Aug-10-20 07:00AM  
Aug-04-20 04:01PM  
Jun-25-20 07:00AM  
07:00AM  
Jun-23-20 07:00AM  
07:00AM  
Jun-15-20 08:15PM  
Jun-04-20 07:00AM  
07:00AM  
May-29-20 07:00AM  
07:00AM  
May-26-20 07:00AM  
07:00AM  
May-18-20 02:47PM  
May-14-20 07:00AM  
07:00AM  
May-13-20 07:00AM  
07:00AM  
May-12-20 10:38AM  
May-08-20 07:00AM  
07:00AM  
May-05-20 03:11PM  
May-04-20 07:00AM  
Apr-30-20 07:00AM  
07:00AM  
Apr-17-20 05:13PM  
Apr-15-20 12:51PM  
Apr-02-20 07:00AM  
07:00AM  
Mar-24-20 07:00AM  
Mar-05-20 04:00PM  
03:00PM  
Feb-28-20 10:15AM  
07:00AM  
Feb-11-20 09:22AM  
Jan-27-20 07:00AM  
Jan-23-20 09:51AM  
Jan-22-20 08:12AM  
07:00AM  
07:00AM  
Jan-21-20 02:40PM  
Jan-13-20 07:00AM  
07:00AM  
Jan-09-20 07:00AM  
Jan-06-20 07:36AM  
Dec-12-19 07:00AM  
Dec-09-19 07:00AM  
Dec-06-19 07:00AM  
Dec-03-19 07:00AM  
Nov-25-19 10:03AM  
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.